| Zarba, Juan J |
| Active, not recruiting | 3 | 368 | Europe, US, RoW | Abemaciclib, Fulvestrant, Placebo | Eli Lilly and Company, Eli Lilly and Company | Breast Neoplasm, Neoplasm Metastasis | 02/24 | 02/26 | | |
CYCLONE 3, NCT05288166: A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer) |
|
|
| Active, not recruiting | 3 | 900 | Europe, Canada, Japan, US, RoW | Abemaciclib, LY2835219, Abiraterone, Prednisone or Prednisolone, Placebo for Abemaciclib | Eli Lilly and Company | Prostatic Neoplasms, Neoplasm Metastasis, Urogenital Neoplasms, Physiological Effects of Drugs, Antineoplastic Agents, Antineoplastic Agents, Hormonal, Androgens, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Abiraterone Acetate, Steroid Synthesis Inhibitors, Cytochrome P-450, Enzyme Inhibitors, Prednisone, Prednisolone, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6 | 02/24 | 10/27 | | |
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer |
|
|
| Recruiting | 3 | 6000 | Europe, Canada, Japan, US, RoW | Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane | Eli Lilly and Company | Breast Neoplasms | 10/27 | 03/32 | | |
| Chen, Xi |
NCT04275323: Safety and Efficacy Study Using Gene Therapy for Critical Limb Ischemia (NL003-CLI-III-1) |
|
|
| Completed | 3 | 302 | RoW | NL003, HGF plasmid, pCK-HGF-X7, Normal Saline, Placebo | Beijing Northland Biotech. Co., Ltd. | Arterial Occlusive Disease, Ischemia, Ulcers, Peripheral Vascular Disease | 06/24 | 06/24 | | |
| Completed | 3 | 242 | RoW | NL003, HGF plasmid, pCK-HGF-X7, Normal Saline, Placebo | Beijing Northland Biotech. Co., Ltd. | Arterial Occlusive Disease, Ischemia, Ulcers, Peripheral Vascular Disease | 12/23 | 12/23 | | |
NCT04385550: A Study of Anlotinib Hydrochloride Capsule Combined With AK105 Injection in Subject With Advanced Gastric and Gastro-oesophageal Junction Adenocarcinoma |
|
|
| Not yet recruiting | 3 | 528 | RoW | Anlotinib hydrochloride capsule, AK105 injection, Paclitaxel injection, Docetaxel injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Gastric and Gastro-oesophageal Junction Adenocarcinoma | 10/23 | 12/23 | | |
| Active, not recruiting | 3 | 654 | Europe, Canada, Japan, US, RoW | Tucatinib, TUKYSA, ONT-380, ARRY-380, Trastuzumab, Herceptin, Herceptin Hylecta, Pertuzumab, Perjeta, Combination product: Trastuzumab + Pertuzumab, Phesgo, Placebo | Seagen Inc., Merck Sharp & Dohme LLC | HER2 Positive Breast Cancer | 05/25 | 10/27 | | |
| Recruiting | 3 | 314 | RoW | Investigational drug: Recombinant Anti-HER2 Humanized Monoclonal Antibody - Monomethyl Auristatin F Conjugates for Injection (FS-1502), Control drug: Trastuzumab emtansine (Kadcyla, T-DM1) | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | Breast Cancer | 07/25 | 01/26 | | |
| Recruiting | 3 | 400 | Europe, Canada, Japan, US, RoW | tucatinib, TUKYSA, ONT-380, ARRY-380, PF-07265792, trastuzumab, Herceptin, bevacizumab, Avastin, cetuximab, Erbitux, oxaliplatin, leucovorin, levoleucovorin, fluorouracil | Seagen Inc., Merck Sharp & Dohme LLC | Colorectal Neoplasms | 08/25 | 04/28 | | |
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer |
|
|
| Recruiting | 3 | 6000 | Europe, Canada, Japan, US, RoW | Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane | Eli Lilly and Company | Breast Neoplasms | 10/27 | 03/32 | | |
NCT05618470: Wumeiwan Jiawei Fang Use in Patients With Blepharospasm |
|
|
| Recruiting | 2/3 | 80 | RoW | Wumeiwan Jiawei Fang, nothing, botulinum toxin A | China Academy of Chinese Medical Sciences | Dry Eye Syndromes, Meige Syndrome, Blepharospasm, Hyperactivity | 08/24 | 09/24 | | |
NCT03941574: A Clinical Study to Evaluate HLX10 Monotherapy for the Treatment of MSI-H or dMMR Solid Tumors That Failed to Respond to Standard Therapy |
|
|
| Recruiting | 2 | 108 | RoW | HLX10 | Shanghai Henlius Biotech | MSI-H Solid Malignant Tumor | 05/24 | 06/26 | | |
NCT05290090: ZR2 Followed by Immunochemotherapy in Elderly Patients With Newly-diagnosed DLBCL |
|
|
| Recruiting | 2 | 31 | RoW | Rituximab, Lenalidomide, Zanubrutinib and RCHOP, BGB-3111 | Zhejiang Cancer Hospital | Diffuse Large B Cell Lymphoma | 06/24 | 12/25 | | |
NCT06674096: RLC Followed by CR-CHOP in Elderly Patients with Newly-diagnosed DEL |
|
|
| Recruiting | 2 | 44 | RoW | RLC-CRCHOP | Zhejiang Cancer Hospital | Double-expressor Lymphoma | 12/29 | 06/30 | | |
NCT05992597: ZR2 Sequential Immunochemotherapy for Newly Treated MCL |
|
|
| Recruiting | 2 | 48 | RoW | ZR2 RDHAP | Zhejiang Cancer Hospital | Rituximab, Lenalidomide, Zebutinib ，Mantle Cell Lymphoma | 08/25 | 12/26 | | |
NCT06086197: A-RGEMOX in the Treatment of Early Relapsed/Refractory DLBCL |
|
|
| Recruiting | 2 | 41 | RoW | Anlotinib hydrochloride, Rituximab, gemcitabine, oxaliplatin | Zhejiang Cancer Hospital | Diffuse Large B-cell Lymphoma Recurrent, Diffuse Large B Cell Lymphoma Refractory | 10/25 | 10/26 | | |
KL264-01, NCT04152499: Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies |
|
|
| Recruiting | 1/2 | 1300 | Canada, US, RoW | SKB264 | Klus Pharma Inc. | Epithelial Ovarian Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Small-Cell Lung Cancer, Endometrial Carcinoma, Head and Neck Squamous Cell Carcinoma, Breast Cancer | 08/25 | 07/26 | | |
NCT03766334: Efficacy and Safety of Highland Barley Diet on Glucose Variability in Patients With Type 1 Diabetes Mellitus |
|
|
| Withdrawn | N/A | 80 | RoW | Highland Barley Diet | Huazhong University of Science and Technology | Type1 Diabetes Mellitus | 10/23 | 12/23 | | |
NCT05685966: Retrospective Study of COVID-19 on Reproductive Function |
|
|
| Recruiting | N/A | 400 | RoW | no intervention | Jinling Hospital, China | COVID-19 | 03/23 | 01/24 | | |
NCT04238520: Functionally-tailored Oral Care Intervention for Community-dwelling Older Adults With Dementia and Their Caregivers |
|
|
| Completed | N/A | 54 | US | Functionally Tailored Oral Care Intervention, Control Intervention | Xi Chen, National Institutes of Health (NIH), National Institute of Nursing Research (NINR) | Dementia, Cognitive Impairment | 08/23 | 08/23 | | |
NCT05750745: A Clinical Study to Evaluate the Efficacy of a Stannous Fluoride Toothpaste for the Relief of Dentine Hypersensitivity in a Chinese Population |
|
|
| Completed | N/A | 245 | RoW | Sensodyne Sensitivity & Gum, Crest Cavity Protection Fresh Lime, Sensodyne Repair and Protect | HALEON | Dentin Sensitivity | 09/23 | 09/23 | | |
NCT05685992: Novel Coronavirus Infection and Reproductive Function |
|
|
| Recruiting | N/A | 400 | RoW | no intervention | Jinling Hospital, China | COVID-19 Infection | 01/24 | 01/24 | | |
NCT06437587: Effects of Appropriate Technology for Home-based Rehabilitation in Patients With Post-stroke Physical Dysfunction |
|
|
| Recruiting | N/A | 72 | RoW | Home-based rehabilitation appropriate technology (S-HRAT) training | Xi Chen, Harbin Medical University | Stroke | 10/24 | 12/24 | | |
| Recruiting | N/A | 236 | US | Investigational ultracompact OCT and OCTA system, optical coherence tomography, optical coherence tomography angiography, retinal photographs, RetCam | Duke University, University of Pennsylvania, National Eye Institute (NEI) | Retinopathy of Prematurity | 03/26 | 03/26 | | |
| Recruiting | N/A | 16 | US | Handheld Optical Coherence Tomography with OCT Angiography, Handheld OCT and OCTA | Duke University, University of Pennsylvania, National Institutes of Health (NIH) | Retinopathy of Prematurity | 08/27 | 08/27 | | |
| Zdenkowski, Nicholas |
FINER, NCT04650581: Fulvestrant and Ipatasertib for Advanced HER-2 Negative and Estrogen Receptor Positive (ER+) Breast Cancer Following Progression on First Line CDK 4/6 Inhibitor and Aromatase Inhibitor |
|
|
| Active, not recruiting | 3 | 250 | Canada, RoW | Ipatasertib, Fulvestrant, Placebo | Canadian Cancer Trials Group, Hoffmann-La Roche | Breast Cancer | 12/24 | 12/26 | | |
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer |
|
|
| Recruiting | 3 | 6000 | Europe, Canada, Japan, US, RoW | Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane | Eli Lilly and Company | Breast Neoplasms | 10/27 | 03/32 | | |
Decrescendo, NCT04675827: De-escalation Adjuvant Chemo in HER2+/ER-/node-neg Early BC Patients Who Achieved PCR After Neoadjuvant Chemo & Dual HER2 Blockade |
|
|
| Terminated | 2 | 139 | Europe, RoW | Pertuzumab and tratuzumab fixed dose combination, Adjuvant pertuzumab + trastuzumab FDC SC for 14 cycles, Fixed-dose combination of Perjeta and Herceptin for subcutaneous injection for 14 cycles, Trastuzumab emtansine, Adjuvant T-DM1 | Jules Bordet Institute, Breast International Group, Hoffmann-La Roche, International Drug Development Institute, Institut Curie | HER2-positive Breast Cancer, ER-Negative Breast Cancer, PR-Negative Breast Cancer, Node-negative Breast Cancer | 11/24 | 11/24 | | |
| Pugliano, Lina |
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer |
|
|
| Recruiting | 3 | 6000 | Europe, Canada, Japan, US, RoW | Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane | Eli Lilly and Company | Breast Neoplasms | 10/27 | 03/32 | | |
